However, a recent study by Zhixiong Ying et al., which used a humanized lipoprotein mouse model (APOE*3-Leiden.CETP), with lipoprotein metabolism similar to humans, demonstrated that treatment with mirabegron does not promote the development of atherosclerosis in this model (Ying et al., 2023). The gene discussed is APOE; the disease is atherosclerosis.